Skip to main content

Fiscal Wizard · Single-issue tearsheet

KLRA / Jun 22, 2026 Run #7602

KLRA

Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Composite verdict

F 23.4 / 100
Bearish setup · Trend Following 13 drivers · 1 gate blocking
  • Engulfing
  • TRIX Zero-Line
  • Volume Climax
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 231st of 598 in Biotechnology

rescore-sweep
Technical synthesis
Bull 0%Evidence: High · 12 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

46.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Return on Capital Employed 76
Free Cash Flow Yield 0
Return on Assets 76
Asset Turnover 25
Greenblatt ROC 75

Technicals Bearish

0.0 / 100

Bearish setup leads (Engulfing, TRIX Zero-Line, Volume Climax); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 15
Engulfing 15
Coppock Curve 17

Risk Gates

1 blocking 3 caution

1 guard active, 12 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Sloan Ratio Caution

Visual accruals-quality flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for KLRA.